Protamine reversal caused less severe thrombocytopenia in the two LMWH groups compared to SH animals, while neutropenia occurred equally in all groups.
INTRODUCTION
The exact mechanisms by which these adverse side effects occur have not been clearly defined.
In contrast to unfractionated standard heparin (SH), the antithrombotic potential of low molecular weight heparin (LMWH) depends on inhibition of factor Xa, and has a lesser effect on factor IIa.
In addition, LMWH appears to have less of an effect on platelets.
Pharmacokinetically, anticoagulant levels of LNWH remain detectable for longer periods of time than with SH. Other potential advantages of LHWH over SH include fewer disturbances of liver function and lipolysis, as well as a lesser demineralizing effect on the skeleton (3).
Recently it was demonstrated that pretreatment with a small dose of protamine before subsequent reversal of SH anticoagulation reduced the adverse hemodynamic and hematologic side effects usually accompanying such reversal. The hemodynamic effects of protamine reversal of anticoagulation achieved with LMWH as well as with SH have recently been assessed with and without protamine pretreatment (1.2). The current study investigates changes in eicosanoids, clotting, and complement factors occurring with reversal of SH and LMWH anticoagulation in an experimental canine model in which a prosthetic graft was placed in the infrarenal aortic position. Hydration was maintained by administration of lactated ringers solution, as a 20 ml/kg bolus followed by a 10 ml/kg/hour infusion. An inferior vena cava catheter was placed transfemorally for blood sampling. Drug administration was performed through a separate peripheral intravenous cannula.
MATERIALS AND METHODS

Eighteen
Systemic arterial blood pressure measurements were made using a catheter in the femoral artery, while pulmonary artery pressures and cardiac output determinations were accomplished with a Swan Ganz catheter threaded from the femoral vein into the pulmonary artery. The infrarenal aorta was exposed through a midline abdominal incision for placement of a 6 mm ID Dacron double velour aortic interposition graft, 5 to 7 cm length. All chromogenic substrate assays were endpoint assays. Standard curves were made from pooled baseline plasma.
Beef heparin related to 3rd Int. Std. was used. C3 was determined by electroimmunophoresis (8). (Table 1) . Depressed platelet counts persisted during the study, but white blood cell counts generally normalized within 10 minutes. Protamine pretreatment in and of itself (Group II) produced a slight reduction (-19%) in platelet count but no effect on the white blood cell count. Antithrombin III and a-2macroglobulin levels were essentially unchanged following protamine reversal in groups I and II (Table 2) .
Anti-Xa levels were greater than 1.0 heparin U/ml after heparinization in all 3 groups. Anti-Xa activity returned to baseline in group III animals but remained elevated in both groups of animals anticoagulated with LMWH (Table 3) .
C-1-esterase inhibitor levels were not statistically changed after protamine reversal in any group, but did tend to increase at 1 and 3 minutes after reversal.
C3 activity did not change significantly in any of the groups (Table 4) .
6-keto-PGFl, levels increased during aortic clamping (+123X) and increased further after reversal in group I. There was no increase in 6-keto-PGFl, during clamping in group II although there was an increase with protamine reversal of heparin (Table 5) . Protamine reversal caused increased activities of TX62 in group I compared to group II (Table 5 ).
LTB4 and LTC4 levels were not significantly altered (Table 6) .
Different assays regarding anticoagulation were used in addition to XaI measurements (Table 7) . SH had a more pronounced effect on TCT and APTT then LHWH.
LMWH with protamine pretreatment (Group II) affected APTT and TCT less than with saline pretreatment (Group I), although the same effect on factor XaI was observed (Table 3) . Failure to document alterations in antithrombin III or Q-2 macroglobulin levels in the current study suggests that thrombin generation or release of proteolytic enzymes is unlikely to be the major factor in causing the adverse effects of protamine.
Other vasoactive substances, released for example from mast cells, could explain the effects of protamine administration.
In this regard histamine release has been documented in these reactions (12). although histamine depletion or receptor blockage has not attenuated these responses (13).
Results of Cl-esterase assays in the present study preclude a major alteration within the bradykinin-system in these reactions, although some increase in C-l-esterase inhibitor leveis was noted.
Many Thus, it is unlikely that prostanoids are the major cause of protamine's side effects.
The leucotrienes did not show any change, but the likelihood that such are uninvolved cannot be claimed inasmuch as leucotrienes are bound to cells and albumin, both of which were extracted in the assay performed in this experiment.
Another potential mechanism accounting for the action of protamine is that this basic protein alters cell membranes (10.17).
SH has two specific binding sites on the endothelial cell membrane, with a higher affinity than LHWH If the short molecular chain of LMWH is unable to be dissociated, then the inability of Xa inhibition to be reversed can easily be explained.
In conclusion, this study has documented that protamine reversal of LMWH or SH anticoagulation does not significantly alter the complement, bradykinin or leucotriene systems, but does cause mild platelet activation, prostacyclin release, and has variable effects on Xa inhibition depending on the type of heparin initially administered.
Protamine reversal of LMWH when compared to SH did not reveal any clear differences in eicosanoids or complement factors, although XaI activity clearly separated these two heparins.
